Mitochondrial Genomics Firm Eyes MDx for Cancer | GenomeWeb

By Tony Fong

NEW YORK (GenomeWeb News) – Leveraging expertise in mitochondrial genomics, a Canadian firm is readying to transition from an R&D shop to a commercial entity.

This week, Mitomics beefed up its management team and board with new additions, and in the coming weeks the firm will launch its first cancer diagnostic test, called Prostate Core Mitomic Test for prostate cancer, as a lab-developed test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.